Resource utility {#S1}
================

These iPSC lines are the first human disease model of AP-4-HSP and provide a valuable resource to study adaptor protein complex 4 biology, disease mechanisms and therapeutic interventions.

Resource details {#S2}
================

The hereditary spastic paraplegias are a group of \> 80 neurodegenerative diseases and the most common cause of inherited spasticity and associated disability ([@R1]). Here, we focus on prototypical yet poorly understood forms of complex hereditary spastic paraplegia in children caused by bi-allelic variants in genes that encode subunits of the adaptor protein complex 4 (AP-4-HSP): SPG47 (*AP4B1*); SPG50 (*AP4M1*), SPG51 (*AP4E1*), and SPG52 (*AP4S1*) ([@R5]). AP-4 is a heterotetrameric protein complex that selectively incorporates transmembrane cargo proteins into vesicles and mediates their intracellular transport. Recently, several groups identified the core autophagy protein ATG9A as the major cargo of AP-4 ([@R2]; [@R3]), linking loss of AP-4 function to defective autophagy. To understand AP-4 deficiency in patient derived cells, we created iPSC lines from three well-characterized patients with *AP4B1*-associated AP-4-HSP (or SPG47) ([@R4]) and sex-matched parents as controls. The *AP4B1* variants present are nonsense, missense, frameshift or canonical splice site mutations leading to no functional protein. Fibroblasts were obtained by standard punch biopsy and reprogrammed using non-integrating Sendai virus to overexpress OCT4, SOX2, KLF4 and hc-MYC. All iPSC lines recovered well after thawing ([Fig. 1A](#F1){ref-type="fig"}, scale bar 400 μm). For each line, one clone was selected based on expression of pluripotency markers and differentiation potential. Pluripotency was assessed by immunofluorescence staining for OCT4, Nanog, SSEA4 and Tra-1--60 ([Fig. 1B](#F1){ref-type="fig"}, scale bar 300 μm) as well as qRT-PCR of NANOG, OCT4, REX1, and SOX2 ([Fig. 1D](#F1){ref-type="fig"}). All iPSC lines showed robust expression of pluripotency markers. To examine the potential to differentiate into all three germ layers, embryoid bodies from iPSC lines were tested for expression of ectodermal (EN1, MAP2 and NR2F2), mesodermal (SNAI2, RGS4 and HAND2) and endodermal (SST, KLF5 and AFP) markers using qRT-PCR ([Fig. 1E](#F1){ref-type="fig"}). Karyotype analysis showed normal karyotypes and no clonal abnormalities ([Fig. 1C](#F1){ref-type="fig"}). STR analysis for 16 short tandem repeat markers ([Table 2](#T2){ref-type="table"}) showed identical profiles for iPSC lines with their respective fibroblast line. To verify *AP4B1* variants in iPSC lines, Sanger sequencing was performed ([Fig. 1F](#F1){ref-type="fig"}). Mycoplasma testing using a standard assay (MycoAlert™) was negative.

Materials and methods {#S3}
=====================

Generation of iPSC {#S4}
------------------

Skin punch biopsies (2--3 mm) were incubated in 0.5% Dispase Solution (STEMCELL Technologies) to remove epidermis. Samples were placed in gelatin-coated wells under growth conditions (37 °C, 5% CO2), and a coverslip was added to prevent lifting. Fibroblast media consisted of DMEM with 10% FBS and 1% Penicillin/Streptomycin (Thermo Fisher Scientific). The CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific) was used to transduce cells ([Tables 1](#T1){ref-type="table"} & [2](#T2){ref-type="table"}). Eight days after transduction, iPSCs were re-plated on Geltrex™-coated dishes and maintained in StemFlex medium (Thermo Fisher Scientific). Emerging stem cell colonies were picked and re-plated on Geltrex™-coated dishes for expansion. Cells were passaged weekly using Gentle Cell Dissociation Reagent (STEMCELL Technologies).

Immunocytochemistry for markers of pluripotency {#S5}
-----------------------------------------------

For immunocytochemistry, iPSC were grown on coverslips. After washing with PBS, cells were fixed in 4% PFA at room temperature for 20 min. After three washes with PBS containing 0.05% Tween 20 (PBST), cells were permeabilized with PBS containing 0.1% Triton X-100 for 15 min and subsequently washed with PBST. Blocking was performed overnight at 4 °C with 4% donkey serum in PBS. After washing with PBS, cells were incubated with primary antibodies ([Table 3](#T3){ref-type="table"}) for 1 h at room temperature, washed with PBST and incubated with secondary antibodies for 1 h at room temperature and stained with DAPI. Imaging was performed using the Olympus IX71 Inverted Microscope.

RNA isolation and qRT-PCR {#S6}
-------------------------

Total RNA isolation was done using RNeasy Mini Kit (Qiagen), and RNA quantification was done using the qScript® cDNA Synthesis Kit (Quanta Bio). qRT-PCR cycles were performed using the QuantStudio 12 K Flex System (Thermo Fisher Scientific).

Embryoid body formation {#S7}
-----------------------

To assess their ability to form three germ layers, iPSCs were lifted in clumps to allow for spontanious EB formation in suspension. iPSC cultures were washed with DPBS and incubated with Accutase (STEMCELL Technologies) for 3 min at 37 °C. Cell clumps were lifted with a cell scraper in EB formation medium, consisting of DMEM, 5% KnockOut™ Serum Replacement and 0.5% Penicillin/Streptomycin (Thermo Fisher Scientific). Clumps were added to a 15 ml tube and settled for 10 min before removing the supernatant. EB formation medium with ROCK inhibitor (STEMCELL Technologies) was added, and cell clumps were plated on ultra-low attachment plates (Corning Costar) for 24 h. EB formation medium was replaced every other day until replating to Gelatin-coated-plates on day 8. Cells were then cultured until day 15 in DMEM with 10% FBS. RNA isolation and qRT-PCR was performed, as described above.

Karyotyping {#S8}
-----------

Karyotyping was performed at WiCell.

Mycoplasma detection {#S9}
--------------------

Testing for mycoplasma contamination was done using the MycoAlert™ Detection Kit (Lonza).

STR profiling {#S10}
-------------

Genomic DNA was isolated from fibroblasts and iPSCs using the DNeasy Blood & Tissue Kit (Qiagen). STR analysis was performed at Genetica DNA Laboratories. Sixteen loci and an additional mouse marker for the detection of mouse DNA contamination were analyzed using the PowerPlex® 16 HS System (Promega).

Mutation verification {#S11}
---------------------

To verify variants in *AP4B1*, PCR was performed on gDNA samples using Platinum PCR SuperMix High Fidelity and the SimpliAmp Thermal Cycler (Thermo Fisher Scientific). PCR products were verified on 1% agarose gel before purification using DNA Clean & Concentrator (Zymo Research) and submitted to Eton Bioscience and Genewiz for Sanger Sequencing.
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Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2019.101575>.
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###### 

Summary of lines.

  iPSC line names   Abbreviation in figures   Gender   Age                Ethnicity   Genotype of locus                               Disease
  ----------------- ------------------------- -------- ------------------ ----------- ----------------------------------------------- --------------------
  BCHNEUi001-A      AP4B1 \[LoF/LoF\]         Male     2 years            Mixed       c.1345A \> T/c.1160_1161delCA                   SPG47
  BCHNEUi002-A      AP4B1 \[WT/LoF\]          Male     38 years           Mixed       c.1160_1161delCA                                Unaffected control
  BCHNEU003-A       AP4B1 \[LoF/LoF\]         Female   3 years            Caucasian   c.530_531insA & c.533_535delACT/c.114-2A \> C   SPG47
  BCHNEUi004-A      AP4B1 \[WT/LoF\]          Female   33 years           Caucasian   c.114-2A \> C                                   Unaffected control
  BCHNEUi005-A      AP4B1 \[LoF/LoF\]         Female   3 years 9 months   Caucasian   c.1216C \> T/c.1328 T \> C                      SPG47
  BCHNEUi006-A      AP4B1 \[WT/LoF\]          Female   39 years           Caucasian   c.1328 T \> C                                   Unaffected control

###### 

Characterization and validation.

  Classification                        Test                                          Result                                                                                                                                                          Data
  ------------------------------------- --------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  Morphology                            Photography                                   *Normal*                                                                                                                                                        [Fig. 1](#F1){ref-type="fig"} *panel A*
  Phenotype                             Qualitative analysis by immunocytochemistry   *Immunocytochemistry for pluripotency markers OCT4, Nanog, SSEA4 and Tra-1--60*                                                                                 [Fig. 1](#F1){ref-type="fig"} *panel B*
                                        Quantitative analysis by RT-qPCR              *qRT-PCR for expression of Nanog OCT4, REX1, SOX, HTERT and DNMT3B*                                                                                             [Fig. 1](#F1){ref-type="fig"} *panel B*
  Genotype                              Karyotype (G-banding) and resolution          *BCHNEUi001-A: 46,XY*                                                                                                                                           [Fig. 1](#F1){ref-type="fig"} *panel E*
                                                                                      *Band Resolution: 425--500*                                                                                                                                     
                                                                                      *BCHNEUi002-A: 46,XY*                                                                                                                                           
                                                                                      *Band Resolution: 400--425*                                                                                                                                     
                                                                                      *BCHNEUi004-A: 46,XX*                                                                                                                                           
                                                                                      *Band Resolution: 375--475*                                                                                                                                     
                                                                                      *BCHNEUi005-A: 46,XX*                                                                                                                                           
                                                                                      *Band Resolution: 425--475*                                                                                                                                     
                                                                                      *BCHNEUi005-A: 46,XX*                                                                                                                                           
                                                                                      *Band Resolution: 425--500*                                                                                                                                     
                                                                                      *BCHNEUi006-A 46,XX*                                                                                                                                            
                                                                                      *Band Resolution: 450--500*                                                                                                                                     
  Identity                              STR analysis                                  *Performed*                                                                                                                                                     *Archived with the journal*
                                                                                      *16 loci tested, all matched (D3S1358, TH01, D21S11, D18S51, Penta E, D5S818, D13S317, D7S820, D16S539, CSF1PO, PentaD, vWA, D8S1179, TPOX, FGA, Amelogenin)*   *Archived with the journal*
  Mutation analysis                     Sanger sequencing                             *Confirmed variants listed in* [Table 1](#T1){ref-type="table"}.                                                                                                [Fig. 1](#F1){ref-type="fig"} *panel F*
                                        Southern Blot OR WGS                          *N/A*                                                                                                                                                           *N/A*
  Microbiology and virology             Mycoplasma                                    *Mycoplasma testing by luminescence (MycoAlert*™*): Negative*                                                                                                   *Archived with the journal*
  Differentiation potential             Embryoid body formation                       *Expression of ectodermal (EN1, MAP2 and NR2F2), mesodermal (SNA1L2, RGS4 and HAND2) and endodermal markers (SST, KLF5 and AFP)*                                [Fig. 1](#F1){ref-type="fig"} *panel D*
  Donor screening (Optional)            HIV 1 + 2 Hepatitis B, Hepatitis C            *N/A*                                                                                                                                                           *N/A*
  Genotype additional info (Optional)   Blood group genotyping                        *N/A*                                                                                                                                                           *N/A*
                                        HLA tissue typing                             *N/A*                                                                                                                                                           *N/A*

###### 

Reagents details.

  Antibodies used for immunocytochemistry                                                   
  ----------------------------------------- --------------------------------------- ------- ------------------------------------------------------------------------------------------------------------------
  Pluripotency markers                      Rabbit anti-OCT4                        1:100   Abcam Cat\# ab19857, RRID:[AB_445175](https://antibodyregistry.org/search.php?q=AB_445175/)
                                            Rabbit anti-NANOG                       1:50    Abcam Cat\# ab21624, RRID:[AB_446437](https://antibodyregistry.org/search.php?q=AB_446437/)
                                            Rat anti-SSEA3                          1:200   MiUipore Cat\# MAB 4303, RRID:[AB_177628](https://antibodyregistry.org/search.php?q=AB_177628/)
                                            Mouse anti-SSEA4                        1:200   MiUipore Cat\# MAB 4304, RRID:[AB_177629](https://antibodyregistry.org/search.php?q=AB_177629/)
                                            Mouse anti-TRA-1--60                    1:200   MiUipore Cat\# MAB 4360, RRID:[AB_10917470](https://antibodyregistry.org/search.php?q=AB_10917470/)
  Secondary antibodies                      AlexaFluor 488 Donkey Anti-Rabbit IgG   1:500   Thermo Fisher Scientific Cat\# A-21206, RRID:[AB_2535792](http://antibodyregistry.org/AB_2535792)
                                            AlexaFluor 488 Donkey Anti-Mouse IgG    1:500   Thermo Fisher Scientific Cat\# A-21202, RRID:[AB_141607](http://antibodyregistry.org/AB_141607)
                                            AlexaFluor 555 Goat Anti-Mouse IgM      1:500   Thermo Fisher Scientific Cat\# A-21426, RRID:[AB_2535847](https://antibodyregistry.org/search.php?q=AB_2535847/)

###### 

Key resource table

  -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Unique stem cell lines identifier      BCHNEUi001-A
                                         BCHNEUi002-A
                                         BCHNEUi003-A
                                         BCHNEUi004-A
                                         BCHNEUi005-A
                                         BCHNEUi006-A
  Alternative names of stem cell lines   HNDS_0052--01
                                         HNDS_0052--03
                                         HNDS_0054--01
                                         HNDS_0054--02
                                         HNDS_0058--01
                                         HNDS_0058--02
  Institution                            Boston Children's Hospital, Harvard Stem Cell Institute
  Contact information of distributor     Darius Ebrahimi-Fakhari <darius.ebrahimi-fakhari@childrens.harvard.edu>
  Type of cell lines                     iPSC
  Origin                                 Human
  Cell Source                            Fibroblasts
  Clonality                              Clonal cell lines
  Method of reprogramming                Sendai Virus, non-integrating (OCT4, SOX2, KLF4 and hc-MYC)
  Multiline rationale                    Three lines from patients with AP-4-HSP due to compound-heterozygous variants in *AP4B1* and control lines from sex-matched parents who are clinically unaffected heterozygous carriers.
  Gene modification                      3 cell lines with homozygous variants
                                         3 cell lines with heterozygous variants
  Type of modification                   N/A
  Associated disease                     *AP4B1* , Hereditary Spastic Paraplegia type 47, SPG47
  Gene/locus                             *AP4B1*; Reference sequences: NM_001253852.1
                                         BCHNEUi001-A: c.1345A \> T/c.1160_1161delCA
                                         BCHNEUi002-A: c.1160_1161delCA
                                         BCHNEUi003-A: c.530_531insA/c.114-2A \> C
                                         BCHNEUi004-A: c.114-2A \> C
                                         BCHNEUi005-A: c.1216C \> T/c.1328T \> C
                                         BCHNEUi006-A: c.1328T \> C
  Method of modification                 N/A
  Name of transgene or resistance        N/A
  Inducible/constitutive system          N/A
  Date archived/stock date               May 3rd 2018
  Cell line repository/bank              N/A
  Ethical approval                       This study was approved by the Institutional Review Board at Boston Children's Hospital (IRB\#: P00016119). Written informed consent was obtained.
  -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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